Press Room

2023 CPhI North America

Start
Tuesday, April 25, 2023 - 00:00
End
Thursday, April 27, 2023 - 00:00
Location: Philadelphia, USA
Booth Number: 723
The Leader in Spray Drying | Hovione

Visit Hovione at CPhI North America - Booth #723 - and discover more about the latest technologies and innovations in drug development.

 

Continuous Tableting for your drug product. The future is continuous | Hovione

The Future is Continuous

Meet our experts and find out if Continuous Tableting is right for your product.

ASD-HIPROS | Hovione

ASD-HIPROS

Learn how this platform can identify the best performing and stable formulations for your drug.

Hovione, The Leader in Spray Drying | Hovione

The Leader in Spray Drying

Know how to improve your drug solubility with the best scale-up science.

Click here and Get in touch today | Hovione

Schedule a meeting today

We look forward to seeing you at CPhI North America and support your project.

 

 

Let’s discuss your project together.

schedule a meeting



 

 

 

Schedule a meeting with our experts.

 

Find more about CPhI North America.

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026